Ambrx, a China-owned Biopharma, Completes $200 Million in Crossover Financing

Ambrx, a San Diego antibody conjugate biopharma owned by China investors, completed an oversubscribed $200 million crossover financing. The company uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. Ambrx says the process creates a new class of therapeutics including next-gen ADCs, bispecifics, and targeted immuno-oncology therapies for cancer, plus smart cytokines for the immune system and therapeutic peptides for metabolic and cardiovascular disease. In 2015, Ambrx was acquired by Fosun Pharma and WuXi AppTec, plus China equity investors HOPU and Everbright. More details....

Stock Symbols: (SHA: 600196; HK: 02196) (SHA: 603259; HK: 2359)